19,087 Shares of Insmed, Inc. $INSM Purchased by Machina Capital S.A.S.

Machina Capital S.A.S. purchased a new position in Insmed, Inc. (NASDAQ:INSM) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 19,087 shares of the biopharmaceutical company’s stock, valued at approximately $2,179,000.

Other institutional investors have also recently modified their holdings of the company. Virginia Estate & Retirement Planning Advisors Inc. purchased a new position in Insmed during the 3rd quarter worth approximately $29,000. SBI Securities Co. Ltd. raised its position in shares of Insmed by 69.4% in the third quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 143 shares during the period. CX Institutional purchased a new position in shares of Insmed in the 3rd quarter valued at about $46,000. Harbor Investment Advisory LLC purchased a new position in shares of Insmed in the 2nd quarter valued at about $52,000. Finally, Heritage Family Offices LLP purchased a new position in shares of Insmed in the 3rd quarter valued at about $60,000.

Insider Buying and Selling

In other Insmed news, Director David Brennan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the sale, the director owned 39,238 shares in the company, valued at $4,865,512. This represents a 38.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.10% of the stock is owned by insiders.

Insmed Stock Down 2.2%

INSM opened at $118.07 on Friday. The business has a fifty day simple moving average of $110.93 and a 200-day simple moving average of $123.57. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The business had revenue of $524.43 million for the quarter, compared to analysts’ expectations of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The firm’s revenue for the quarter was up 268.4% on a year-over-year basis. During the same quarter last year, the company earned ($1.75) earnings per share. On average, equities analysts predict that Insmed, Inc. will post -1.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on INSM. Barclays reduced their price target on Insmed from $237.00 to $207.00 and set an “overweight” rating for the company in a report on Wednesday, September 30th. Wolfe Research cut Insmed from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. HC Wainwright assumed coverage on shares of Insmed in a report on Wednesday, November 4th. They set a “buy” rating and a $220.00 target price for the company. Morgan Stanley dropped their price target on Insmed from $218.00 to $213.00 and set an “overweight” rating for the company in a research report on Wednesday, October 21st. Finally, Truist Financial reissued a “buy” rating and issued a $195.00 price objective (up from $185.00) on shares of Insmed in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $196.52.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.